Home›Oncology› Dabrafenib and trametinib produce rapid response in a single case of BRAF V600E-mutant PHC
Dabrafenib and trametinib produce rapid response in a single case of BRAF V600E-mutant PHCTargeted Treatment Shows Promise for Rare Pancreatic Cancer Type
Frontiers in MedicinePublished August 19, 2026DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Note that dabrafenib plus trametinib may be effective in BRAF V600E-mutant PHC, but evidence is limited by small sample size.
This systematic review and case report examine pancreatic hepatoid carcinoma (PHC), a rare malignancy. The analysis includes 57 cases of PHC to establish baseline outcomes, where the 1-year overall survival rate was 70.7% and the 3-year overall survival rate was 43.1%.
A single case report detailed a patient with BRAF V600E-mutant PHC treated with dabrafenib plus trametinib. This patient achieved a rapid and deep response, with AFP levels returning to the normal range within approximately two months and a partial response recorded.
The authors note significant limitations, including the small sample size for the specific mutation (n=1) and the overall rarity of PHC cases. While these findings suggest BRAF V600E as a clinically actionable driver in PHC, the association between the mutation and treatment response is based on only one case. Clinical application remains limited by low certainty due to the scarcity of data.
How this fits prior evidence
This finding addresses a gap regarding targeted therapies for rare pancreatic malignancies. While previous evidence noted that lenvatinib plus pembrolizumab did not improve overall survival compared to standard of care in second-line HNSCC, this report explores different molecular drivers and combinations for PHC. The identification of BRAF V600E as a potentially actionable driver provides a specific target for patients with this rare mutation.
Researchers analyzed cases of pancreatic hepatoid carcinoma, which is a rare form of pancreatic cancer. The study included a systematic analysis of 57 patients and a detailed report on one specific case involving a BRAF V600E mutation.
A patient with this specific genetic mutation received a combination of dabrafenib and trametinib. This treatment led to a rapid and deep response, where the patient's AFP levels returned to a normal range within about two months. While the results for this individual were positive, the overall survival rate for 57 patients with this cancer type was 70.7% at one year and 43.1% at three years.
It is important to note that these findings are based on a very small sample size of only one patient for the specific mutation studied. Because pancreatic hepatoid carcinoma is rare, there is low certainty regarding how well this treatment will work for others. These results suggest that certain genetic markers might be useful for identifying who could benefit from targeted therapies, but more research is needed.
What this means for you:
A targeted drug combination showed a strong response in one patient with a specific mutation in rare pancreatic cancer.
Common questions
What was the result of the dabrafenib and trametinib treatment?
In one case study, a patient with a specific BRAF V600E mutation showed a rapid and deep response to the combination of dabrafenib and trametinib. Their AFP levels returned to the normal range within approximately two months, and a partial response was recorded.
How common is this type of pancreatic cancer?
Pancreatic hepatoid carcinoma is considered a rare form of pancreatic cancer. The study analyzed 57 cases in total to look at survival rates, which were 70.7% at one year and 43.1% at three years.
Is this treatment proven for all patients with this cancer?
No, the evidence is not yet enough to say it works for everyone. Because there was only one patient in the study with the specific BRAF mutation, the results are based on a very small sample size and have low certainty.
BackgroundPancreatic hepatoid carcinoma (PHC) is an extremely rare pancreatic malignancy characterized pathologically by hepatocellular-like differentiation. Some patients may present with elevated serum alpha-fetoprotein (AFP). Owing to the limited number of reported cases, the clinical features, molecular characteristics, and systemic treatment strategies for PHC remain poorly defined. BRAF V600E is an actionable alteration with established therapeutic value in several solid tumors; however, its clinical significance in PHC remains unclear.Case presentationWe report the case of a 64-year-old man with advanced PHC who presented with painless jaundice, dark urine, and recent weight loss. Laboratory tests showed marked cholestatic liver injury and significantly elevated AFP. Imaging revealed a pancreatic head-neck mass with portal vein tumor thrombus and regional lymph node metastases, corresponding to cT4N1M1, stage IV disease. Percutaneous transhepatic biliary drainage was first performed to relieve obstructive jaundice. Biopsy of the pancreatic lesion showed poorly differentiated carcinoma. Based on hepatoid morphology, immunophenotype, elevated serum AFP, imaging findings, and exclusion of primary hepatocellular carcinoma, the patient was diagnosed with PHC. Comprehensive genomic profiling identified a BRAF V600E mutation with a variant allele frequency of 31.89%, together with MDM2 and MYC amplification. The molecular profile was characterized by microsatellite stability, low tumor mutational burden, MGMT promoter methylation, and low PD-L1 expression. After two cycles of pembrolizumab-based first-line therapy combined with paclitaxel, S-1, and lenvatinib, AFP continued to increase and imaging showed rapid tumor enlargement, consistent with immune checkpoint inhibitor-related hyperprogressive disease. The treatment was then switched to dabrafenib plus trametinib. AFP declined rapidly and returned to the normal range within approximately two months. Imaging showed marked regression of the pancreatic primary lesion, disappearance of the portal vein tumor thrombus and metastatic lymph nodes, and conversion of peripheral blood minimal residual disease to negative. The best response was partial response. After approximately six months of targeted therapy, occult disease progression emerged. Subsequent addition of cetuximab, replacement of the MEK inhibitor, and dose escalation of targeted therapy did not restore sustained systemic disease control, although local disease remained manageable with subsequent treatment adjustments. Proton radiotherapy was then delivered to the residual pancreatic lesion, followed by CyberKnife radiotherapy for a newly detected 2.3-cm metastasis in the caudate lobe of the liver. As of April 2026, the patient’s AFP level remained close to normal at 14 ng/mL, local lesions were well controlled, peripheral blood minimal residual disease had turned positive, and the patient remained in a stable tumor-bearing state.Systematic analysisWe further summarized 57 previously reported cases of PHC. The median age was 54 years, and 66.7% of patients were male. Tumors occurred at different pancreatic sites, including the pancreatic head in 21 cases, body in 8 cases, tail in 13 cases, and multifocal lesions in 15 cases. More than half of the patients had metastatic disease at initial diagnosis. The immunophenotype of PHC was highly heterogeneous. Regarding treatment, 47 patients underwent surgery, 20 received chemotherapy, and 6 received targeted therapy. The 1-year and 3-year overall survival rates were 70.7% and 43.1%, respectively, indicating an overall poor prognosis.ConclusionThis case suggests that BRAF V600E may represent a clinically actionable driver alteration in PHC. Dabrafenib plus trametinib induced a rapid and deep response in this patient with advanced BRAF V600E-mutant PHC. Microsatellite stability, low tumor mutational burden, low PD-L1 expression, and MDM2 amplification may be associated with limited benefit from immunotherapy and a risk of hyperprogression. After resistance to targeted therapy, local radiotherapy may serve as an important strategy for controlling oligoresidual and oligometastatic lesions. Together with the literature review, this case supports early comprehensive molecular profiling and individualized multidisciplinary management for advanced PHC.
